Login / Signup

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.

Jurij HanželNejc SeverIvan FerkoljBorut ŠtabucNataša SmrekarTina KurentMatic KoželjGregor NovakGriet CompernolleSophie TopsAnn GilsDavid Drobne
Published in: United European gastroenterology journal (2019)
Early vedolizumab trough levels predicted combined endoscopic and clinical remission highlighting their possible use in clinical practice.
Keyphrases
  • ulcerative colitis
  • clinical practice
  • ultrasound guided
  • patients with inflammatory bowel disease
  • rheumatoid arthritis